The Trillium II Prize

Purpose

The purpose of this prize is to promote the use of the FHIR international patient summary (IPS).

Background

International patient summary (IPS) standards consistently adapted and localized to serve the needs of specific use cases are essential to attaining a vision of the patient summary as a social good and human right. Trillium II builds on previous recommendations to put IPS standards at the core of a global community for digital health innovation with the aim of advancing patient safety and trust by bridging the gap between strategic intent and capability to deliver interoperability at a global scale.

Award criteria

The intention is to award the Trillium Prize to the organisation that, in the opinion of the panel of judges, has done the most to promote the beneficial use of the FHIR IPS for international medical information exchanges. The specific criteria are:

  • Conformance to the specification
  • Ease of interface to EHRs/PHRs (input and output)
  • Numbers and types of patients/persons for whom an IPS was generated
  • Ease of access by patient while abroad
  • Options for download, redistribution, sharing, directing
  • Benefit realisation and anticipated future impact.

Timetable

The prize will be formally announced at the Connected Health Conference 2018 event in Boston Mass. USA on 17th October 2018. All the key documents relevant to the IPS that have been finalised to date are available for download on the website at https://trillium2.eu/deliverables/.

The competition will close on 1st May 2019. Winners will be announced at an appropriate event in Europe a month thereafter.

Value

In addition to the promotional benefits from winning the prize, there will be a cash award of €1,000.

Judging panel

The following have been invited to judge the Prize:

  • Kathi Apostolidis, President – Hellenic Cancer Federation-ELL.O.K.
  • Christopher Chute, Chief Research Information Officer for Johns Hopkins Medicine
  • Marc Lange, Secretary General, European Health Telematics Association (EHTEL), Belgium
  • Jeremy Thorp, Director of Business Architecture, NHS UK
  • Mike Short, Chief Scientific Adviser, Department for International Trade, UK
  • Dee O’Sullivan, Director, myhealthapps.net at PatientView

We will be inviting at least three more judges, at least two of whom we hope to be US-based.

Process

Depending on the level of interest in the prize, a subcommittee of Alexander Berler, Catherine Chronaki, Charles Lowe and Janne Rasmussen may select a shortlist of entries for the above to judge. Shortlist selection will be based on the criteria on the previous page.

Eligibility

We are especially keen for SMEs and not-for-profits to apply although any organisation can enter the competition, other than the participants in the Trillium II consortium. Partnerships may enter though only if one organisation in the partnership accepts the lead role.

Registration and application details

All competitors are required to register with MedCom (Lene Taustrup, lta@medcom.dk) in order to ensure that they have immediate access to the online registration form and all the updates to the definition of the IPS, and other relevant data that are produced during the competition period, so that they are working from a level playing field. Entries should be in English only. The online form will work to the following format:

  • Applicant details – name, organisation, address including country, other contact details, organisation type, ultimate organisation owner/s.
  • Organisational role – how your organisation can use the IPS to improve international healthcare delivery; who you have worked with to do this (if any other organisation(s). Max 300 words
  • IPS implementation details – how you have put the IPS to use; the type of healthcare service you are using it in; the specifics of the application. Max 300 words.
  • Results – what the results have been so far, ideally quantitively in terms of people affected, benefit received and improved patient outcomes, including who has verified the results, otherwise qualitatively. Max 300 words.
  • The future – extrapolate into the future what benefits your use of the ILS will deliver – please give a rationale and justification for your projection so the judges can decide how likely it is to happen. Max 300 words

Further information or questions

Please contact charles.lowe@dhaca.org.uk

Blog at WordPress.com.

Up ↑

%d bloggers like this: